Skip to main content
Cardiolucent

Treatment

Antiarrhythmic Medications

Drug therapy to control rhythm and prevent recurrent arrhythmia.

Antiarrhythmic medications are used to convert an abnormal rhythm back to normal sinus rhythm, to prevent recurrence, or to reduce the burden of arrhythmia episodes. They are grouped into classes based on their primary mechanism — sodium channel blockers (Class I, including flecainide and propafenone), beta-blockers (Class II), potassium channel blockers (Class III, including amiodarone, sotalol, and dofetilide), and calcium channel blockers (Class IV). Each class has specific indications, monitoring requirements, and proarrhythmic risk. Dr. Kedan selects and monitors these medications with awareness of your underlying structural heart disease, kidney and liver function, and other therapy.

What This Treatment Approach Includes

  • Selection between rate control and rhythm control strategies
  • Choice of agent based on structural heart disease, kidney/liver function, and other medications
  • Baseline EKG, electrolytes, and organ-function labs before initiation
  • Ongoing rhythm monitoring with EKG, Holter, or extended wearable
  • Periodic surveillance for class-specific side effects (thyroid, liver, pulmonary, QT prolongation)
  • Coordination with electrophysiology when ablation becomes the better option
  • Direct access to discuss symptoms, missed doses, or new interactions

How It Works

Antiarrhythmic drugs modify the electrical properties of cardiac tissue by blocking specific ion channels (sodium, potassium, calcium) or modulating autonomic input (beta-blockers). The effect is to slow conduction, prolong refractoriness, or suppress abnormal automaticity — making it harder for arrhythmia circuits to sustain. Different agents target different parts of the action potential, which is why drug choice matches the specific arrhythmia and the patient's underlying heart.

Who This Is For

  • Atrial fibrillation or atrial flutter where rhythm control is preferred over rate control
  • Symptomatic supraventricular tachycardia not yet ready for ablation
  • Frequent or symptomatic PVCs causing fatigue or LV dysfunction
  • Ventricular arrhythmias in patients with or without structural heart disease
  • Post-cardioversion maintenance of sinus rhythm
  • Patients with implantable defibrillators experiencing recurrent shocks
  • Bridge therapy while awaiting or recovering from an ablation procedure

Monitoring and Follow-Up

Each antiarrhythmic class has specific monitoring needs: amiodarone requires periodic thyroid, liver, and pulmonary surveillance; sotalol and dofetilide require QT interval monitoring; flecainide and propafenone are avoided in significant coronary disease and require EKG follow-up. Initial follow-up is close — within weeks of starting — with longer intervals once stable. The concierge model allows same-day EKG and labs when symptoms or scheduled monitoring suggest a problem.

How Cardiolucent Manages This

Antiarrhythmic therapy benefits from a longitudinal cardiologist who knows your imaging, prior rhythm history, and overall risk profile rather than from episodic encounters. Dr. Kedan personally selects the agent, sets the monitoring cadence, and coordinates with electrophysiology when ablation becomes the better long-term option. Extended visits make the rate-versus-rhythm conversation possible, and direct access between visits handles dose changes, side effects, and new interactions in real time.

Common Questions

Frequently Asked Questions

What is the difference between rate control and rhythm control?
Rate control accepts the arrhythmia (typically atrial fibrillation) and uses medications to keep the heart rate in a safe range. Rhythm control aims to restore and maintain normal sinus rhythm using antiarrhythmic drugs and sometimes cardioversion or ablation. The choice depends on symptoms, age, atrial size, prior arrhythmia duration, and patient preference — and the right answer for many patients shifts over time.
Which patients benefit most from antiarrhythmic medications?
Symptomatic atrial fibrillation or flutter, recurrent SVT, ventricular arrhythmias in structural or non-structural heart disease, and patients with implantable defibrillators experiencing frequent shocks all commonly benefit. The benefit-versus-risk calculation depends heavily on the specific drug and your underlying heart structure.
Are antiarrhythmic drugs safe?
When properly selected and monitored, yes — but they require respect. The category includes some of cardiology's most effective drugs and some with significant proarrhythmic potential (paradoxically causing new arrhythmias) or organ toxicity. Matching drug to patient and following the monitoring schedule is what keeps them safe.
What are common side effects?
Side effects are class-specific: amiodarone can affect thyroid, liver, lungs, eyes, and skin over time; sotalol and dofetilide can prolong the QT interval; flecainide and propafenone can rarely worsen arrhythmia in patients with coronary disease. Beta-blockers and calcium channel blockers used for rate control can cause fatigue or low heart rate. Dr. Kedan reviews the specific profile before starting.
What monitoring is needed?
Baseline EKG, electrolytes, and organ-function labs are standard. After initiation, follow-up EKG and rhythm monitoring confirm the drug is doing its job. Long-term monitoring varies by drug — amiodarone requires periodic thyroid, liver, and pulmonary surveillance; sotalol requires QT and kidney function tracking; others are simpler. The schedule is set per medication.
How long will I be on the medication?
Duration depends on the arrhythmia and your trajectory. Some patients stay on long-term suppressive therapy; others use it as a bridge while awaiting an ablation; others stop after a sustained period of stable sinus rhythm. The plan is revisited at each follow-up rather than left static.
When is ablation a better choice than continued drug therapy?
When medications fail, are not tolerated, or are projected to be needed for many years, ablation often becomes the better long-term strategy — particularly for atrial fibrillation and SVT. Recent guidelines support earlier ablation referral than was common a decade ago. Dr. Kedan reassesses the balance at each visit.
What drug interactions matter?
Many — particularly with amiodarone, which affects warfarin, digoxin, statins, and others. QT-prolonging interactions matter for sotalol and dofetilide. Calcium channel and beta-blocker interactions can compound heart rate slowing. Always disclose every new medication, including over-the-counter products and supplements, before starting.
What about pregnancy and antiarrhythmic drugs?
Some antiarrhythmics have established safety profiles in pregnancy; others should be avoided. The conversation must happen before or as early as possible during pregnancy, ideally with maternal-fetal medicine involvement. Dr. Kedan coordinates this when relevant.
How do I start antiarrhythmic therapy with Dr. Kedan?
Schedule a consultation at the Beverly Hills office with prior EKGs, rhythm monitor data, echocardiogram, and a current medication list. Cardiolucent is a concierge practice and does not bill Medicare or insurance, though a detailed superbill is provided for out-of-network reimbursement. Call (310) 304-5555 or use the contact form.

Explore

Related Treatments

Considering antiarrhythmic therapy?

Discuss this treatment with Dr. Kedan in Beverly Hills.
Schedule an Appointment

Medical Disclaimer

The information on this site is for general educational purposes only and is not medical advice, diagnosis, or treatment. Reading this site does not create a doctor–patient relationship. Always consult a qualified healthcare professional for personal guidance. If this is an emergency, call 911. Mentions of medications, devices, or procedures are informational and not endorsements. Full medical disclaimer.

†Some listed indications involve investigational/off-label use. Learn more.